Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab.

Samantha Epistolio,Marco Cefalì,Paolo Spina,Francesca Molinari, Alessandra Movilia,Massimiliano Cergnul,Luca Mazzucchelli,Sara De Dosso,Milo Frattini,Piercarlo Saletti

Oncotarget（2021）

引用 4|浏览5

暂无评分

摘要

Most of mCRC patients treated with bevacizumab-containing regimens experience a strong reduction of RAS mutant cells, suggesting bevacizumab as particularly active against RAS mutant cells. This finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure.

查看译文

关键词

RAS mutations,bevacizumab,metastatic colorectal cancer,next-generation sequencing

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要